Effects of flecainide, encainide, and clofilium on ventricular refractory period extension by transcardiac shocks

PACE - Pacing and Clinical Electrophysiology

Volumn 19, Issue 1, 1996, Pages 50-60

  Sweeney, Robert J ^a   Gill, Robert M ^a   Steinberg, Mitchell I ^a   Reid, Philip R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

antiarrhythmic drugs; defibrillation; electric countershock; refractory period extension; ventricular fibrillation

Indexed keywords

CLOFILIUM; ENCAINIDE; FLECAINIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DOG; DRUG EFFECT; ELECTRIC SHOCK; HEART ELECTROPHYSIOLOGY; HEART EXCITATION; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; POTASSIUM CONDUCTANCE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIAC PACING, ARTIFICIAL; DOGS; ELECTRIC COUNTERSHOCK; ENCAINIDE; FLECAINIDE; HEART CONDUCTION SYSTEM; QUATERNARY AMMONIUM COMPOUNDS; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; TIME FACTORS; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION;

EID: 0030059215     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1996.tb04790.x     Document Type: Article

References (43)

1. Babbs CF. Alteration of defibrillation threshold by antiarrhythmic drugs: A theoretical framework. Crit Care Med 1981; 9:362-363.
2. Marinchak RA, Freihling TD, Kline RA, et al. Effect of anti-arrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the literature. PACE 1988; 11:7-12.
3. Babbs CF, Yim GKW, Whistler SJ, et al. Evaluation of ventricular defibrillalion threshold in dogs by antiarrhythmic drugs. Am Heart J 1979; 98: 345-350.
4. Tacker WA, Niebauer MJ, Babbs CF, et al. The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med 1980; 8:177-180.
5. Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: Sodium channel block and action potential prolongation. Circulation 1989; 79: 1106-1117.
6. Singer I, Guarnieri T, Kupersmith J. Implanted automatic defibrillators: Effects of drugs and pacemakers. PACE 1988; 11:2250-2262.
7. Deeb GM, Hardesty RL, Griffith BP, et al. The effects of cardiovascular drugs on the defibrillation threshold and the pathological effects on the heart using an automated implantable defibrillators. Ann Thorac Surg 1983; 35:361-366.
8. Dorian P, Fain ES, Davy JM, et al. Effect of quinidine and bretylium on defibrillation energy requirements. Am Heart J 1986; 112:19-25.
9. Kerber RE, Pandian NG, Jensen SR, et al. Effect of lidocaine and bretylium on energy requirement for transthoracic defibrillalion: Experimental studies. J Am Coll Cardiol 1986; 7:397-405.
10. Natale A, Jones DL, Kim YH, et al. Effects of lidocame on defibrillation threshold in the pig: Evidence of anesthesia related increase. PACE 1991; 14:1239-1244.
11. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J 1987; 114: 8-17.
12. Frame LH. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. PACE 1989; 12:339-346.
13. Guarnieri T, Levine JH, Veltri EP, et al. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator. Am J Cardiol 1987; 60: 1061-1064.
14. Sweeney RJ, Gill RM, Steinberg MI, et al. Ventricular refractory period extension caused by defibrillation shocks. Circulation 1990; 82:965-972.
15. Sweeney RJ, Gill RM, Reid PR. Characterization of refractory period extension by transcardiac shock. Circulation 1991; 83:2057-2066.
16. Zhou X, Knisley SB, Wolf PD, et al. Prolongation of repolarization time by electric field stimulation with monophasic and biphasic shocks in open-chest dogs. Circ Res 1991; 68:1761-1767.
17. Knisley SB, Smith WM, Ideker RE. Effect of field stimulation on cellular repolarization in rabbit myocardium: Implications for reentry induction. Circ Res 1992; 70:707-715.
18. Sweeney RJ, Gill RM, Reid PR. An in-vitro model of electrical defibrillation. (abstract) J Am Coll Cardiol 1993; 21(Suppl.):307A.
19. Daubert JP, Frazier DW, Wolf PD, et al. Response of relatively refractory canine myocardium to monophasic and biphasic shocks. Circulation 1991; 84:2522-2538.
20. Dillon SM. Synchronized repolarization after defibrillation shocks: A possible component of the defibrillation process demonstrated by optical recordings in rabbit heart. Circulation 1992; 85: 1865-1878.
21. Dillon SM, Mehra R. Prolongation of ventricular refractoriness by defibrillation shocks may be due to additional depolarization of the action potential. J Cardiovasc Electrophysiol 1992; 3:442-457.
22. Steinberg MI, Sullivan ME, Weist SA, et al. Cellular electrophysiology of clofilium, a new antifibrillatory agent, in normal and ischemic canine Purkinje fibers. J Cardiovasc Pharmacol 1981; 3:881-895.
23. Steinberg MI, Michelson EL. Cardiac electrophysiologic effects of specific class III substances. In HJ Reiser, LN Horowitz (eds.): Mechanisms and Treatments of Cardiac Arrhythmias; Relevance of Basic Studios to Clinical Management. Baltimore-Munich, Urban & Schwarzenberg, 1985, pp. 263-281.
24. Dorian P, Wang M, David I, et al. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation 1991; 83:614-621.
25. Estes NAM, Garan H, Ruskin JN. Electrophysiologic properties of flecainide acetate. Am J Cardiol 1984; 53:26B-29B.
26. Ikeda N, Singh BN, Davis LD, et al. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 1985; 5:303-310.
27. Brugada J, Boersma L, Kirchhof C, et al. Proarrhythmic effects of flecainide: Experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation 1991; 84:1808-1818.
28. Varro A, Nakaya Y, Elharrar V, et al. Effect of antiarrhythmic drugs on the cycle length-dependent action potential duration in dog Purkinje and ventricular muscle fibers. J Cardiovasc Pharmacol 1980; 8:178-185.
29. Hellestrand KJ, Nathan AW, Bexton RS, et al. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds. Am J Cardiol 1984; 53:30B-38B.
30. O'Hara G, Villemaire C, Talajic M, et al. Effects of flecainide on the rate dependence of a trial refractoriness, atrial repolarization and atrioventricular node conduction in anesthetized dogs. J Am Coll Cardiol 1992; 19:1335-1342.
31. Che'zalviel F, Weissenburger J, Ertzbischoff O, et al. Comparison of the cardiac electrophysiological effects of flecainide and hydroquinidine in anesthetized dog: Concentration-response relationship. J Cardiovasc Pharmacol 1990; 15:50-56.
32. Guehler J, Gornick CC, Tobler HG, et al. Electrophysiologic effects of flecainide acetate and its major metabolites in the canine heart. Am J Cardiol 1985; 55:807-812.
33. Hernandez R, Mann DE, Breckinridge S, et al. Effects of flocainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 1989; 14: 777-781.
34. Sweeney RJ, Gill RM, Reid PR. Antiarrhythmic drugs and the relationship between refractory period extension and defibrillation thresholds. (abstract) PACE 1991; 14:689.
35. Fain ES, Dorian P, Davy JM, et al. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986; 73:1334-1341.
36. Frazier DW, Wolf PD, Wharton JM, et al. Stimulus-induced critical point mechanism for electrical initiation of reentry in normal canine myocardium. J Clin Invest 1988; 83:1039-1052.
37. Sami M, Mason JW, OH G, et al. Canine eloctrophysiology of encainide, a new antiarrhythmic drug. Am J Cardiol 1979; 43:1149-1154.
38. Van Gelder I, Crijns HJGM, Van Gilst WH, et al. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989; 63:112-114.
39. Murakawa Y, Sezaki K, Inoue H, et al. Shock-induced refractory period extension and pharmacological modulation of defibrillation threshold. J Cardiovasc Pharmacol 1994; 23:822-825.
40. Szabo TS, Jones DL, McQuinn RL, et al. Flecainide acetate does not alter the energy requiremnts for direct ventricular defibrillation using sequential pulse defibrillation in pigs. J Cardiovasc Pharmacol 1988; 12:377-383.
41. Natale A, Jones DL, Kleinstiver PW, et al. Effects of flecainide on defibrillation threshold in pigs. J Cardiovasc Pharmacol 1993; 21:573-577.
42. Gill RM, Sweeney RJ, Reid PR. Refractory period extension at fibrillatory activation rates. (abstract) PACE 1994; 17:808.
43. Sweeney RJ, Gill RM, Reid PR. Refractory period extension for monophasic versus biphasic shocks. (abstract) J Am Coll Cardiol 1994; Feb:422A.